Curated News
By: NewsRamp Editorial Staff
July 14, 2026

Formycon and OneSource Join Forces for Biosimilar Manufacturing

Discuss on Substack Discuss on Telegram
Original Source

TLDR

  • Formycon gains cost-efficient manufacturing from OneSource, boosting its competitive edge in biosimilar markets.
  • OneSource provides integrated Drug Substance and Drug Product manufacturing from its Bangalore facility supporting Formycon's biosimilar programs.
  • This partnership expands global access to affordable biosimilars, improving healthcare for patients worldwide.
  • OneSource's five FDA and EMA approved facilities enable scalable production of complex biologics.

Impact - Why it Matters

This partnership matters because it strengthens the global supply chain for affordable biosimilars, which are critical for treating serious and chronic diseases. By combining Formycon's development prowess with OneSource's cost-efficient manufacturing in India, the collaboration aims to reduce healthcare costs and expand patient access to life-changing therapies worldwide, especially as patents on major biologics expire in the coming years.

Summary

Formycon AG and OneSource Specialty Pharma Limited announced a strategic manufacturing partnership for biosimilars, combining Formycon's development excellence with OneSource's end-to-end biologics manufacturing capabilities. Under the agreement, OneSource will serve as a strategic manufacturing partner, providing integrated Drug Substance and Drug Product manufacturing from its facility in Bangalore, India. This collaboration aims to support Formycon's biosimilar programs for global markets, leveraging OneSource's state-of-the-art biologics facility and regulatory approvals from agencies like the US FDA and EMA.

Dr. Stefan Glombitza, CEO of Formycon AG, emphasized that adding OneSource to their network of strategic partners strengthens supply capabilities with a focus on quality, operational excellence, and cost-efficiency, aligning with the FYB4Growth strategy. Neeraj Sharma, MD & CEO of OneSource, highlighted that the partnership expands access to high-quality, affordable biologics for patients worldwide and reinforces India's role as a global hub for biologics manufacturing. The partnership reflects a shared commitment to advancing global access to biosimilars through sustainable, cost-effective manufacturing models.

Formycon brings a strong track record in biosimilar development with marketed products like FYB201/ranibizumab, FYB202/ustekinumab, and FYB203/aflibercept, and pipeline candidates including FYB206/pembrolizumab and FYB208/dupilumab. OneSource complements this with an integrated biologics platform, five manufacturing facilities approved by global regulators, and expertise across biologics, sterile injectables, and drug-device combinations. The partnership is poised to drive scalability and efficiency, supporting Formycon's FYB4Growth pillars of geographic diversification, smart portfolio strategy, excellence and innovation, and cost efficiency. View the original release on NEWMEDIAWIRE.

Source Statement

This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Formycon and OneSource Join Forces for Biosimilar Manufacturing

blockchain registration record for this content.